CRYSTALENS ACCOMMODATING IOL AT52SE UNKNOWN CRYSTALENS IOL

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a literature report with the FDA on 2020-02-07 for CRYSTALENS ACCOMMODATING IOL AT52SE UNKNOWN CRYSTALENS IOL manufactured by Bausch + Lomb.

Event Text Entries

[178262906] This case was documented in "two cases of z syndrome with the crystalens after uneventful cataract surgery" by leonard yuen, md, william trattler, md, brian s. Boxer wachler, md. (journal of cataract & refractive surgery 2008; ascrs and escrs). Study author has indicated that there is no further information on this case. The product lot number and serial number are unknown. The product is not available for evaluation. The investigation is ongoing. (b)(4).
Patient Sequence No: 1, Text Type: N, H10


[178262907] Published article - case 2 of 2. A patient who had a monofocal intraocular lens (iol) in the right eye desired cataract surgery in the left eye. The patient previously had a scleral buckle procedure in the left eye. The patient opted for an accommodating iol in the left eye to enhance the near vision in the nondominant eye. Uneventful iol implantation was performed in the left eye. At the one-week visit, the ucdva was 20/40 with a manifest refraction of -0. 25 -1. 00 x75, and the best spectacle-corrected visual acuity (bscva) was 20/20-2. Four weeks later, the patient reported ocular ache and decreased vision. The patient consulted an eye, nose, and throat specialist and sinusitis was ruled out. A retinal specialist also ruled out pain related to the scleral buckle. The manifest refraction was -0. 75 -1. 25 x 80. Slitlamp examination showed no other abnormalities. At nine weeks, the patient presented with continuing eye pain and an increased minus sphere on manifest refraction, -3. 25 -0. 75 x 80, with uncorrected visual acuity (ucva) of 20/60-2. Dilated examination showed the appearance of a z syndrome with stress lines visible on the posterior capsule. An nd:yag laser posterior capsulotomy was performed. Additional laser treatment was applied to areas of the posterior capsule fibrosis that appeared to contribute to the z syndrome. The iol moved back into the proper position during and immediately after the laser treatment. The chronic eye pain also resolved immediately after the nd:yag laser capsulotomy. The manifest refraction was plano -0. 75 x 170; the bscva was 20/25 and the ucdva was 20/40. The intermediate ucva was 20/25, and the near ucva was j2-. Study author has indicated that there is no further information on this case.
Patient Sequence No: 1, Text Type: D, B5


MAUDE Entry Details

Report Number0001313525-2020-00028
MDR Report Key9681580
Report SourceLITERATURE
Date Received2020-02-07
Date of Report2020-01-09
Date of Event2008-11-01
Report Date2005-01-01
Date Reported to FDA2005-01-01
Date Reported to Mfgr2005-01-10
Date Mfgr Received2020-02-07
Date Added to Maude2020-02-07
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Health Professional3
Initial Report to FDA3
Report to FDA3
Event Location3
Manufacturer ContactSTEPHANIE ANASTASIOU
Manufacturer Street21 NORTH PARK PLACE BLVD.
Manufacturer CityCLEARWATER FL 33759
Manufacturer CountryUS
Manufacturer Postal33759
Manufacturer Phone7277246659
Single Use0
Previous Use Code0
Event Type3
Type of Report3

Device Sequence Number: 1

Brand NameCRYSTALENS ACCOMMODATING IOL
Generic NameLENS, INTRAOCULAR, ACCOMMODATIVE
Product CodeNAA
Date Received2020-02-07
Model NumberAT52SE UNKNOWN CRYSTALENS IOL
Lot NumberUNKNOWN
OperatorHEALTH PROFESSIONAL
Device AvailabilityN
Device AgeDA
Device Sequence No1
Device Event Key0
ManufacturerBAUSCH + LOMB
Manufacturer Address1400 N. GOODMAN ROCHESTER NY 14609 US 14609

Device Sequence Number: 101

Product Code---
Date Received2020-02-07
Device Sequence No101
Device Event Key0


Patients

Patient NumberTreatmentOutcomeDate
101. Required No Informationntervention 2020-02-07

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.